Yes I know. By the time it returned to market TPA had taken control of the market due to its reduced cost. Urokinase had been one of the largest budgeted formulary items so when it returned the vast majority of hospitals wouldnt allow it back on formulary. Shortly thereafter, Abbott sold the drug to a company out of Canada called Microbix. It never really recovered but at the time of its initial removal it was the dominant drug in the market. Yes I am still bitter over the whole ordeal lol. Regards.
Market Data 
Markets 
AI
